These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 25748864)

  • 21. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
    George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
    Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similar clinical characteristics of familial and sporadic inflammatory bowel disease in South Korea.
    Chung SH; Park SJ; Lee HS; Hong SP; Cheon JH; Kim TI; Kim WH
    World J Gastroenterol; 2014 Dec; 20(45):17120-6. PubMed ID: 25493025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug utilization of biologic therapy in Crohn's disease and ulcerative colitis: a population-based Danish cohort study 2015-2020.
    Jensen KJ; Jensen CB; Wennerström C; Burisch J; Petersen J
    Scand J Gastroenterol; 2023 Jul; 58(7):726-736. PubMed ID: 36802972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rates and Predictors of Vaccinations Among Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Agents.
    Pham HV; Hasan I; Udaltsova N; Pham K; Abramson O; Armstrong MA; Postlethwaite D; Li D
    Dig Dis Sci; 2018 Jan; 63(1):209-217. PubMed ID: 28836068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study.
    Fumery M; Dupont C; Ley D; Savoye G; Bertrand V; Guillon N; Wils P; Gower-Rousseau C; Sarter H; Turck D; Leroyer A
    Dig Liver Dis; 2024 Jan; 56(1):21-28. PubMed ID: 37137808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study.
    Charpentier C; Salleron J; Savoye G; Fumery M; Merle V; Laberenne JE; Vasseur F; Dupas JL; Cortot A; Dauchet L; Peyrin-Biroulet L; Lerebours E; Colombel JF; Gower-Rousseau C
    Gut; 2014 Mar; 63(3):423-32. PubMed ID: 23408350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.
    Assa A; Hartman C; Weiss B; Broide E; Rosenbach Y; Zevit N; Bujanover Y; Shamir R
    J Crohns Colitis; 2013 Jun; 7(5):369-76. PubMed ID: 22483567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
    Burisch J
    Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A
    Romero-Cara P; Torres-Moreno D; Pedregosa J; Vílchez JA; García-Simón MS; Ruiz-Merino G; Morán-Sanchez S; Conesa-Zamora P
    Int J Med Sci; 2018; 15(1):10-15. PubMed ID: 29333082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Anti-TNFα Agents and Time to First-time Surgery in Paediatric Patients with Ulcerative Colitis and Crohn's Disease.
    Larsen MD; Qvist N; Nielsen J; Kjeldsen J; Nielsen RG; Nørgård BM
    J Crohns Colitis; 2016 Jun; 10(6):650-6. PubMed ID: 26802081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
    Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
    Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
    Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
    J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
    van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
    Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease.
    Karmi N; Bangma A; Spekhorst LM; van Dullemen HM; Visschedijk MC; Dijkstra G; Weersma RK; Voskuil MD; Festen EAM
    PLoS One; 2021; 16(9):e0256860. PubMed ID: 34534227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
    Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
    Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.